AX-2025-021065 · Liraglutide · WXT lot WXT-2504-L4924

Section 1

Results

Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 35 min gradient, 214 nm	96.74	% area	≥ 97.5	FAIL
Total impurities	RP-HPLC, sum of reported peaks	3.26	% area	≤ 2.5	FAIL
Largest single impurity	RP-HPLC — des-His1 truncate (−137 Da)	1.17	% area	≤ 1.00	FAIL
Identity — theoretical monoisotopic mass	calculated from molecular formula	3748.9631	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	3748.9470	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-4.3	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	86.77	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	83.94	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	18.55	mg	15 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	15.571	mg	15 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	103.8	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	5.91	%	≤ 8.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	6.74	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.58	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	membrane filtration, USP <71>, 14 d	No growth at 14 d	—	no growth	PASS
Appearance	visual, diffuse light, black and white background	Off-white lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.35	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 35 min gradient	19.82	min	19.93 ± 0.40 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.28	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	52,861	—	≥ 20,000	PASS
Resolution to nearest impurity	vs γ-Glu regioisomer	1.35	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 35 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 52,861, and skew follows the reported asymmetry factor of 1.28. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 1.17 % impurity against a 96.74 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Liraglutide — main peak	19.82	4,701,864	96.74	—
2	des-His1 truncate (−137 Da)	18.63	56,866	1.17	-137.059
3	γ-Glu regioisomer	20.30	41,799	0.86	0.000
4	des-palmitoyl liraglutide (−238 Da)	15.81	28,190	0.58	-238.230
5	deamidated (Asn→Asp, +1 Da)	19.26	19,441	0.40	+0.984
6	liraglutide dimer	23.50	7,290	0.15	+3748.963
7	palmitoyl bis-adduct (+238 Da)	23.18	4,860	0.10	+238.230
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 3748.9631 Da, computed from C172H265N43O51. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 3748.9470 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
6+	625.8345	625.8318	-0.0027	8.3
5+	750.7999	750.7967	-0.0032	59.6
4+	938.2481	938.2440	-0.0041	100.0
3+	1250.6616	1250.6563	-0.0053	59.3
2+	1875.4888	1875.4808	-0.0080	8.8

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	5.91
Counter-ion (acetate)	ion chromatography	6.74
Residual solvent + inorganic residue	estimated	0.58
Total peptide content	by difference	86.77
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	97.5	96.74	divergence +0.72 pp vs batch median
Total impurities (% area)	2.50	3.26
Largest single impurity (% area)	1.81	1.17
Water (%)	not stated	5.91
Counter-ion (%)	not stated	6.74
Peptide content (%w/w)	not stated	86.77
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Laboratory-retained
Evidentiary weight: Provenance documented, selection uncontrolled.
Chain of custody: Laboratory retained sample (−20 °C, 19 d since original receipt) → re-assay.
Assay date: 25 Sep 2025
Submitted to the index: 14 Oct 2025
Laboratory: Nordanalyt Laboratories, Uppsala, Sweden
Method basis: 35 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot WXT-2504-L4924 n=9

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-021059	WXT-2504-L4924	Medutest	2025-Q3	96.70	5.85	—	Supplier-supplied	1	FAIL
AX-2025-021060	WXT-2504-L4924	Janoshik	2025-Q3	96.78	6.07	—	Buyer-sourced	1	FAIL
AX-2025-021061	WXT-2504-L4924	Janoshik	2025-Q3	96.45	6.76	—	Buyer-sourced	2	FAIL
AX-2025-021062	WXT-2504-L4924	Janoshik	2025-Q3	97.19	6.26	98.8	Supplier-supplied	2	FAIL
AX-2025-021063	WXT-2504-L4924	Janoshik	2025-Q3	97.17	6.30	—	Supplier-supplied	1	FAIL
AX-2025-021064	WXT-2504-L4924	Kestrel	2025-Q3	97.18	6.60	96.1	Supplier-supplied	1	FAIL
AX-2025-021066	WXT-2504-L4924	Janoshik	2025-Q3	96.78	5.60	107.0	Buyer-sourced	1	FAIL
AX-2025-021067	WXT-2504-L4924	Janoshik	2025-Q3	96.59	6.57	98.0	Supplier-supplied	1	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Liraglutide records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041275	WWB	WWB-2607-X2189	Nordanalyt	2026-Q3	99.61	5.03	97.3	Supplier-supplied	0	PASS
AX-2026-043335	CPC	CPC-2602-G1978	Janoshik	2026-Q3	97.29	4.91	—	Laboratory-retained	1	FAIL
AX-2026-043332	CPC	CPC-2602-G1978	Janoshik	2026-Q3	97.16	4.88	91.3	Supplier-supplied	1	FAIL
AX-2026-041271	WWB	WWB-2607-X2189	Medutest	2026-Q3	99.93	5.24	95.8	Supplier-supplied	0	PASS
AX-2026-043336	CPC	CPC-2602-G1978	Janoshik	2026-Q3	97.69	4.58	104.9	Supplier-supplied	1	MARGINAL
AX-2026-041652	QSC	QSC-2605-W8602	Nordanalyt	2026-Q3	99.33	6.55	—	Supplier-supplied	0	PASS
AX-2026-041273	WWB	WWB-2607-X2189	Janoshik	2026-Q3	99.87	4.27	—	Supplier-supplied	0	PASS
AX-2026-041272	WWB	WWB-2607-X2189	Janoshik	2026-Q3	99.15	4.12	97.2	Supplier-supplied	0	PASS

Other recent WXT records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043488	Pramlintide	WXT-2603-D6052	Janoshik	2026-Q3	97.87	4.37	—	Supplier-supplied	1	MARGINAL
AX-2026-043406	Semaglutide	WXT-2604-C4728	Janoshik	2026-Q3	97.24	4.65	—	Supplier-supplied	1	MARGINAL
AX-2026-043421	Sermorelin	WXT-2608-P4867	Janoshik	2026-Q3	98.15	3.09	—	Supplier-supplied	0	PASS
AX-2026-043420	Sermorelin	WXT-2608-P4867	Medutest	2026-Q3	98.62	3.07	96.4	Supplier-supplied	0	PASS
AX-2026-043423	Sermorelin	WXT-2608-P4867	Janoshik	2026-Q3	98.28	3.86	98.5	Buyer-sourced	0	PASS
AX-2026-043401	Semaglutide	WXT-2604-C4728	Medutest	2026-Q3	97.70	4.78	91.5	Supplier-supplied	1	MARGINAL
AX-2026-043400	Semaglutide	WXT-2604-C4728	Nordanalyt	2026-Q3	96.86	4.11	106.4	Laboratory-retained	1	FAIL
AX-2026-043422	Sermorelin	WXT-2608-P4867	Medutest	2026-Q3	98.35	3.59	—	Supplier-supplied	1	MARGINAL